Loading…

Xenotransplantation of neonatal porcine bone marrow‐derived mesenchymal stem cells improves murine hind limb ischemia through lymphangiogenesis and angiogenesis

Background The clinical utility of stem cell therapy for peripheral artery disease has not been fully discussed, and one obstacle is limited donor supplies. In this study, we attempted to rescue mouse ischemic hind limb by xenotransplantation of neonatal porcine bone marrow‐derived mesenchymal stem...

Full description

Saved in:
Bibliographic Details
Published in:Xenotransplantation (Københaven) 2021-07, Vol.28 (4), p.e12693-n/a
Main Authors: Yamada, Hideaki, Sakata, Naoaki, Nishimura, Masuhiro, Tanaka, Tomoko, Shimizu, Masayuki, Yoshimatsu, Gumpei, Kawakami, Ryo, Wada, Hideichi, Sawamoto, Osamu, Matsumoto, Shinichi, Kodama, Shohta
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The clinical utility of stem cell therapy for peripheral artery disease has not been fully discussed, and one obstacle is limited donor supplies. In this study, we attempted to rescue mouse ischemic hind limb by xenotransplantation of neonatal porcine bone marrow‐derived mesenchymal stem cells (npBM‐MSCs). Methods Neonatal porcine bone marrow‐derived mesenchymal stem cells were transplanted to ischemic hind limbs of male C57BL/6J mice (npBM‐MSCs group). Mice with syngeneic transplantation of mouse BM‐MSCs (mBM‐MSCs group) were also prepared for comparison. The angiogenic effects were evaluated by recovery of blood flow on laser Doppler imaging, histologic findings, and genetic and protein levels of angiogenic factors. Results Regarding laser Doppler assessments, blood flow in the hind limb was rapidly recovered in the npBM‐MSCs group, compared with that in the mBM‐MSCs group (P = .016). Compared with the mBM‐MSCs group, the npBM‐MSCs group had early and prominent lymphangiogenesis [P 
ISSN:0908-665X
1399-3089
DOI:10.1111/xen.12693